Cargando…
An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases
PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T M...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996243/ https://www.ncbi.nlm.nih.gov/pubmed/36910023 http://dx.doi.org/10.1016/j.ctro.2023.100602 |
_version_ | 1784902999057891328 |
---|---|
author | Ding, Shouliang Liu, Biaoshui Zheng, Shiyang Wang, Daquan Liu, Mingzhi Liu, Hongdong Zhang, Pengxin Peng, Kangqiang He, Haoqiang Zhou, Rui Guo, Jinyu Qiu, Bo Huang, Xiaoyan Liu, Hui |
author_facet | Ding, Shouliang Liu, Biaoshui Zheng, Shiyang Wang, Daquan Liu, Mingzhi Liu, Hongdong Zhang, Pengxin Peng, Kangqiang He, Haoqiang Zhou, Rui Guo, Jinyu Qiu, Bo Huang, Xiaoyan Liu, Hui |
author_sort | Ding, Shouliang |
collection | PubMed |
description | PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T MR-Linac. The FSRT fractions employed daily MR scans and the contours were utilized to create each adapted plan. The brain lesions and perilesional edema were delineated on MR images of pre-treatment simulation (Fx0) and all fractions (Fx1, Fx2, Fx3, Fx4 and Fx5) to evaluate the inter-fractional changes. These changes were quantified using absolute/relative volume, Dice similarity coefficient (DSC) and Hausdorff distance (HD) metrics. Planning target volume (PTV) coverage and organ at risk (OAR) constraints were used to compare non-adaptive and adaptive plans. RESULTS: A total of 28 patients with 88 lesions were evaluated, and 23 patients (23/28, 82.1%) had primary lung adenocarcinoma. Significant tumor volume reduction had been found during FSRT compared to Fx0 for all 88 lesions (median −0.75%, −5.33%, −9.32%, −17.96% and −27.73% at Fx1, Fx2, Fx3, Fx4 and Fx5, p < 0.05). There were 47 (47/88, 53.4%) lesions being accompanied by perilesional edema and the inter-fractional changes were significantly different compared to those without perilesional edema (p < 0.001). Patients with multiple lesions (13/28, 46.4%) had more significant inter-fractional tumor changes than those with single lesion (15/28, 53.6%), including tumor volume reduction and anatomical shift (p < 0.001). PTV coverage of non-adaptive plans was below the prescribed coverage in 26/140 fractions (19%), with 12 (9%) failing by more than 10%. All 140 adaptive fractions met prescribed target coverage. The adaptive plans also had lower dose to whole brain than non-adaptive plans (p < 0.001). CONCLUSIONS: Significant inter-fractional tumor changes could be found during FSRT in patients with BMs treated on the 1.5 T MR-Linac. Daily MR-guided re-optimization of treatment plans showed dosimetric benefit in patients with perilesional edema or multiple lesions. |
format | Online Article Text |
id | pubmed-9996243 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-99962432023-03-10 An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases Ding, Shouliang Liu, Biaoshui Zheng, Shiyang Wang, Daquan Liu, Mingzhi Liu, Hongdong Zhang, Pengxin Peng, Kangqiang He, Haoqiang Zhou, Rui Guo, Jinyu Qiu, Bo Huang, Xiaoyan Liu, Hui Clin Transl Radiat Oncol Original Research Article PURPOSE: To assess the feasibility and potential benefits of online adaptive MR-guided fractionated stereotatic radiotherapy (FSRT) in patients with brain metastases (BMs). METHODS AND MATERIALS: Twenty-eight consecutive patients with BMs were treated with FSRT of 30 Gy in 5 fractions on the 1.5 T MR-Linac. The FSRT fractions employed daily MR scans and the contours were utilized to create each adapted plan. The brain lesions and perilesional edema were delineated on MR images of pre-treatment simulation (Fx0) and all fractions (Fx1, Fx2, Fx3, Fx4 and Fx5) to evaluate the inter-fractional changes. These changes were quantified using absolute/relative volume, Dice similarity coefficient (DSC) and Hausdorff distance (HD) metrics. Planning target volume (PTV) coverage and organ at risk (OAR) constraints were used to compare non-adaptive and adaptive plans. RESULTS: A total of 28 patients with 88 lesions were evaluated, and 23 patients (23/28, 82.1%) had primary lung adenocarcinoma. Significant tumor volume reduction had been found during FSRT compared to Fx0 for all 88 lesions (median −0.75%, −5.33%, −9.32%, −17.96% and −27.73% at Fx1, Fx2, Fx3, Fx4 and Fx5, p < 0.05). There were 47 (47/88, 53.4%) lesions being accompanied by perilesional edema and the inter-fractional changes were significantly different compared to those without perilesional edema (p < 0.001). Patients with multiple lesions (13/28, 46.4%) had more significant inter-fractional tumor changes than those with single lesion (15/28, 53.6%), including tumor volume reduction and anatomical shift (p < 0.001). PTV coverage of non-adaptive plans was below the prescribed coverage in 26/140 fractions (19%), with 12 (9%) failing by more than 10%. All 140 adaptive fractions met prescribed target coverage. The adaptive plans also had lower dose to whole brain than non-adaptive plans (p < 0.001). CONCLUSIONS: Significant inter-fractional tumor changes could be found during FSRT in patients with BMs treated on the 1.5 T MR-Linac. Daily MR-guided re-optimization of treatment plans showed dosimetric benefit in patients with perilesional edema or multiple lesions. Elsevier 2023-02-23 /pmc/articles/PMC9996243/ /pubmed/36910023 http://dx.doi.org/10.1016/j.ctro.2023.100602 Text en © 2023 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Research Article Ding, Shouliang Liu, Biaoshui Zheng, Shiyang Wang, Daquan Liu, Mingzhi Liu, Hongdong Zhang, Pengxin Peng, Kangqiang He, Haoqiang Zhou, Rui Guo, Jinyu Qiu, Bo Huang, Xiaoyan Liu, Hui An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases |
title | An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases |
title_full | An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases |
title_fullStr | An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases |
title_full_unstemmed | An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases |
title_short | An exploratory analysis of MR-guided fractionated stereotactic radiotherapy in patients with brain metastases |
title_sort | exploratory analysis of mr-guided fractionated stereotactic radiotherapy in patients with brain metastases |
topic | Original Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9996243/ https://www.ncbi.nlm.nih.gov/pubmed/36910023 http://dx.doi.org/10.1016/j.ctro.2023.100602 |
work_keys_str_mv | AT dingshouliang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liubiaoshui anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT zhengshiyang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT wangdaquan anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liumingzhi anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liuhongdong anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT zhangpengxin anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT pengkangqiang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT hehaoqiang anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT zhourui anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT guojinyu anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT qiubo anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT huangxiaoyan anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liuhui anexploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT dingshouliang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liubiaoshui exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT zhengshiyang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT wangdaquan exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liumingzhi exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liuhongdong exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT zhangpengxin exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT pengkangqiang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT hehaoqiang exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT zhourui exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT guojinyu exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT qiubo exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT huangxiaoyan exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases AT liuhui exploratoryanalysisofmrguidedfractionatedstereotacticradiotherapyinpatientswithbrainmetastases |